Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-dose escalation study of CAL-120 in healthy male volunteers
NL-OMON35937Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonhematologic neoplasms comparing CAL-120 with Placebo (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetics of CAL-120 and 1 more. Started Mar 2011; status: active, not recruiting.
02
Drugs
acalisib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON35937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35937.